IP Library Granted Patent US 9,138,478
Granted Patent B2
US 9,138,478 · App. 14/186,940 · Granted Sep 22, 2015

Substituted chroman derivatives, medicaments and use in therapy

Inventors: Andrew Heaton (Alexandria, AU); Alan James Husband (Pyrmont, AU)
Assignee: MEI Pharma, Inc.
A61K45/06A23L1/30A23L2/52A61K31/353C07D311/38C07D311/58A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,138,478
App. No.
14/186,940
Granted
Sep 22, 2015
Kind
B2
Abstract

Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Claims (17)

1. A method for the treatment of cancer or a tumour mass, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I-b):

wherein

R 1 is C 1-6 alkyl;

the drawing “ ” and R 2 together represent a double bond;

R 3 , R 4 and R 5 are independently hydrogen, hydroxy, C 1-6 alkoxy, or C 1-6 alkyl;

R 6 is hydrogen;

R 7 is C 1-6 alkoxy;

R 8 and R 9 are independently hydrogen, hydroxy, halo, C 1-6 alkoxy, or C 1-6 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the cancer or tumour mass is of epithelial origin, of mesenchymal origin, or of neural origin.

3. The method of claim 2 , wherein the cancer or tumour mass of epithelial origin is prostate, ovarian, cervical, breast, gall-bladder, pancreatic, colorectal, renal, or non-small lung cancer.

4. The method of claim 2 , wherein the cancer or tumour mass of mesenchymal origin is melanoma, mesothelioma, or sarcoma cancer.

5. The method of claim 2 , wherein the cancer or tumour mass of neural origin is glioma.

6. The method of claim 1 , wherein the compound is simultaneously administered with an anti-cancer agent.

7. The method of claim 1 , wherein the compound is sequentially administered with an anti-cancer agent.

8. The method of claim 6 , wherein the anti-cancer agent is cisplatin, dehydroequol, or paclitaxel.

9. The method of claim 7 , wherein the anti-cancer agent is cisplatin, dehydroequol, or paclitaxel.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: HEATON, ANDREW; HUSBAND, ALAN
To: NOVOGEN RESEARCH PTY LTD
Reel/Frame 036379/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2015
From: NOVOGEN LIMITED
To: MARSHALL EDWARDS, INC.
Reel/Frame 036379/0716 →
CHANGE OF NAME Recorded Aug 20, 2015
From: MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 036379/0785 →
Priority Claims (1)
WO PCT/AU2004/001619 · Nov 19, 2004 · international
Continuity (6)
Continuation 13293947 · Nov 10, 2011
Continuation 12551277 · Aug 31, 2009
Division 11230726 · Sep 21, 2005
Provisional Application 60611300 · Sep 21, 2004
Provisional Application 60676934 · May 3, 2005
Related Publication 20140170243A1 · Jun 19, 2014